from the aug 7 update: NanoLogix announces it has
Post# of 9144
(Total Views: 488)
Posted On: 08/28/2020 6:40:42 PM
from the aug 7 update:
NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.
The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test . Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.
While we have achieved results in less than one hour with our own laboratory work, indications from one of the entities are that the test can potentially be streamlined to the point where results may be obtained in as little as twenty minutes in a form that makes the test more user and consumer friendly. This projected ease of use positions the assay for potential home use if and when it is approved by the FDA.
Read More: https://investorshangout.com/post/view?id=587...z6WSFE6O5z
several purposes to the refinement work -reduce time from sub 1hr to ca 20 minutes so its much more useful as a point of care test -especially given the widespread societal attention deficit syndrome
its not the twenties anymore - Bret cant turn in his notes on his own lab work developing the test -the test has to be tested-run through protocols - biotech is very big on protocols -that info can then be used to obtain Emergency Use Authorization- so the test can be marketed
biotech is not one of my fields -but EUA may wake up other companies to partner in NNLX's efforts, depending on the specifics of the contract with the houston lab and the west coast co
somebody can address the issue of whether obtaining the eua will result in govt funding
possibility of two peer reviewed papers - this will reach the biotech community-reaching the scientists -bypassing the roadblocks presented by business and lawyer groups- who can then be informed by scientists -i dont remember reading much about peer reviewed articles presented by other covid tests
the refinements can be used possibly retroactively for grants-though if EUA govt funding is provided that may very well outshine any grants
NanoLogix announces it has begun working with two entities to refine and further develop its patent-pending Rapid Viral Assay for COVID19 and other viruses. One is a West Coast diagnostic company and the other a long-established independent Houston laboratory.
The overall intent of this work is to obtain results to enable a detailed submission of those results to the US FDA for the purpose of receiving an Emergency Use Authorization, enabling use of the technology as a Point of Care (POC) rapid test . Secondary benefits should be publication of the resulting data in the form of at least two peer-reviewed science/medical journal papers. Grant applications are anticipated by at least one of the partners to the work. The projections for the timeline for the work range from one+ month for the independent laboratory to more than three months for the diagnostic company.
While we have achieved results in less than one hour with our own laboratory work, indications from one of the entities are that the test can potentially be streamlined to the point where results may be obtained in as little as twenty minutes in a form that makes the test more user and consumer friendly. This projected ease of use positions the assay for potential home use if and when it is approved by the FDA.
Read More: https://investorshangout.com/post/view?id=587...z6WSFE6O5z
several purposes to the refinement work -reduce time from sub 1hr to ca 20 minutes so its much more useful as a point of care test -especially given the widespread societal attention deficit syndrome
its not the twenties anymore - Bret cant turn in his notes on his own lab work developing the test -the test has to be tested-run through protocols - biotech is very big on protocols -that info can then be used to obtain Emergency Use Authorization- so the test can be marketed
biotech is not one of my fields -but EUA may wake up other companies to partner in NNLX's efforts, depending on the specifics of the contract with the houston lab and the west coast co
somebody can address the issue of whether obtaining the eua will result in govt funding
possibility of two peer reviewed papers - this will reach the biotech community-reaching the scientists -bypassing the roadblocks presented by business and lawyer groups- who can then be informed by scientists -i dont remember reading much about peer reviewed articles presented by other covid tests
the refinements can be used possibly retroactively for grants-though if EUA govt funding is provided that may very well outshine any grants
(2)
(0)